Status:
TERMINATED
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer, and most recently trials have supported the use of transdermal estrogens (patch) in the patient population wi...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with metastatic prostate adenocarcinoma, who have failed initial hormone therapy and who have had progression after at least one chemotherapy regimen that included docetaxel. Patients on antiandrogens must have progression after withdrawal of the antiandrogen for 4 weeks (flutamide) or 6 weeks (bicalutamide).
- PSA ≥ 10 ng/ml.
- Patients who have received LHRH agonist therapy for \> 1 month must maintain agonist therapy while on-study. Patients who have not received agonist therapy or received \< 1 month of therapy, may not begin or continue agonist therapy while on-study.
- Age \>18 years and an estimated life expectancy of at least 4 months.
- ECOG performance status ≤ 2 (see Appendix B).
- Full recovery from the effects of any prior surgery or radiation therapy within 4 weeks of study entry.
- Serum creatinine ≤ 1.5 x ULN
- Total bilirubin \< ULN
- Transaminases (SGOT and/or SGPT) ≤ 2 X institutional upper limit.
- Capacity to give informed, written consent.
- Exclusion Criteria
- Any coexisting medical condition precluding full compliance with the study.
- Any history of deep venous thrombosis (DVT) or pulmonary embolus. Patients with a DVT on anticoagulants for ≥ 6 months will be eligible.
- Known CNS metastasis.
- The discontinuation of flutamide or bicalutamide \< 4 or 6 weeks respectively.
- History of severe cardiovascular disease (AHA class III or IV; see Appendix C), uncontrolled CHF or life threatening cardiac dysrhythmia in the past 6 months.
- Herbal supplements may not be used while on-study and patients must have discontinued use for ≥ 1 week before entering on-study.
- Patients with a known hypersensitivity to estrogen.
- Triglyceride \> 200 mg/dl.
- Prior estramustine.
Exclusion
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00176644
Start Date
May 1 2005
End Date
December 1 2008
Last Update
September 13 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CentraState Healthcare System
Freehold, New Jersey, United States, 07728
2
Robert Wood Johnson University Hospital/CINJ at Hamilton
Hamilton, New Jersey, United States, 08690
3
Morristown Memorial Hospital
Morristown, New Jersey, United States, 07692
4
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901